Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan Capecitabine and Celecoxib.
Latest Information Update: 15 Jan 2024
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Celecoxib (Primary) ; Irinotecan (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 10 Jan 2024 Status changed from completed to discontinued.
- 16 Oct 2008 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 16 Oct 2008 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.